Get the Stockscreener App
2.07
6.70%
0.13
After Hours:
2.06
-0.010
-0.48%
Palisade Bio Inc stock is traded at $2.07, with a volume of 4.93M.
It is up +6.70% in the last 24 hours and up +140.78% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.94
Open:
$1.99
24h Volume:
4.93M
Relative Volume:
0.61
Market Cap:
$18.88M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.148
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
+18.97%
1M Performance:
+140.78%
6M Performance:
+166.72%
1Y Performance:
-23.90%
1-Day Range:
$1.92
$2.09
1-Week Range:
$1.61
$2.14
52-Week Range:
$0.53
$3.30
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
2.07 | 271.14M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio Inc. stock momentum explainedBull Run & Fast Exit/Entry Strategy Plans - newser.com
Is Palisade Bio Inc. stock attractive for retirement portfolios2025 Winners & Losers & Long-Term Growth Plans - newser.com
Palisade Bio Inc. recovery potential after sell offRate Cut & Long-Term Capital Growth Strategies - newser.com
Automated trading signals detected on Palisade Bio Inc.Quarterly Growth Report & Free Safe Capital Growth Stock Tips - newser.com
How to track smart money flows in Palisade Bio Inc.Trade Exit Summary & Weekly High Potential Alerts - newser.com
What sentiment indicators say about Palisade Bio Inc. stockJuly 2025 Fed Impact & Community Consensus Picks - newser.com
Why Palisade Bio Inc. (7NS0) stock could outperform next year2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Using data filters to optimize entry into Palisade Bio Inc.2025 Dividend Review & Verified Entry Point Detection - newser.com
Will Palisade Bio Inc. stock benefit from AI adoptionShare Buyback & Detailed Earnings Play Alerts - newser.com
Should I hold or sell Palisade Bio Inc. stock in 2025Quarterly Market Summary & Daily Oversold Stock Bounce Ideas - newser.com
Is Palisade Bio Inc. stock trading near support levelsJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Can volume confirm reversal in Palisade Bio Inc.Volume Spike & Reliable Price Action Trade Plans - newser.com
Palisade Bio’s Unexpected Surge: Analyzing Recent Developments - StocksToTrade
Palisade Bio appoints Sharon Skare as VP of global clinical operations - Investing.com Australia
Forecasting Palisade Bio Inc. price range with options dataJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - newser.com
Palisade Bio Inc Stock Analysis and ForecastTrading Volume Surges & Access High Yield Alerts - earlytimes.in
Will Palisade Bio Inc. stock maintain momentum in 2025July 2025 Intraday Action & Community Consensus Trade Signals - fcp.pa.gov.br
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations - The Manila Times
Palisade Bio (NASDAQ: PALI) appoints Sharon Skare; IND planned H1 2026 for PALI-2108 - Stock Titan
What MACD and RSI say about Palisade Bio Inc.Weekly Investment Summary & AI Powered Trade Plan Recommendations - newser.com
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):